C-Path launches consortium to support medical product development in sickle cell disease

(Critical Path Institute (C-Path)) C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news